The Global Multiple System Atrophy Therapeutics Market Size accounted for USD 141.2 Million in 2024 and is estimated to achieve a market size of USD 213.3 Million by 2033 growing at a CAGR of 4.8% from 2025 to 2033.

Multiple System Atrophy Therapeutics Market Highlights

• Global multiple system atrophy therapeutics market revenue is poised to garner USD 213.3 Million by 2033 with a CAGR of 4.8% from 2025 to 2033
• North America multiple system atrophy therapeutics market value occupied around USD 51.72 million in 2024
• Asia-Pacific multiple system atrophy therapeutics market growth will record a CAGR of more than 5.5% from 2025 to 2033
• Among product, the anle-138b sub-segment generated 57% of share in 2024
• Focus on developing novel therapies, including gene and stem cell treatments is a popular market trend that fuels the industry demand

Multiple system atrophy (MSA) therapies are medical treatments that aim to regulate the symptoms and progression of multiple system atrophy, a rare neurological disease. MSA affects the autonomic nervous system, movement, and coordination, resulting in symptoms such as muscle rigidity, tremors, urinary problems, and blood pressure anomalies. There is currently no treatment for MSA, thus medicines are mostly aimed at symptom management and enhancing patients' quality of life. Furthermore, advances in diagnostic techniques are assisting in early discovery, allowing for timely treatment intervention to mitigate the disease's impact. As a result, the MSA therapeutics market is changing, with more investment in novel drug research and clinical trials.

Global Multiple System Atrophy Therapeutics Market Dynamics

Market Drivers

• Increasing prevalence of multiple system atrophy (MSA) due to the aging global population
• Growing research and development activities aimed at developing new treatment options for MSA
• Advancements in diagnostic techniques enhancing early detection and management of MSA

Market Restraints

• Limited treatment options currently available for MSA, focusing mainly on symptom management
• Challenges in accurate and early diagnosis due to symptom overlap with other neurodegenerative disorders
• High costs associated with research and development, leading to expensive therapeutic options

Market Opportunities

• Development of disease-modifying therapies targeting the underlying causes of MSA
• Expansion into emerging markets with increasing healthcare infrastructure and awareness
• Collaborations between pharmaceutical companies and research institutions to accelerate innovative treatment development

Multiple System Atrophy Therapeutics Market Report Coverage

Multiple System Atrophy Therapeutics Market Insights

As the world's population ages, the prevalence of neurodegenerative illnesses, including MSA, rises. For example, the World Health Organization (WHO) estimates that neurological diseases affect more than one in every three individuals, making them the biggest cause of illness and disability globally. More than 80% of neurological deaths and health loss occur in low- and middle-income countries, and access to treatment varies greatly. As a result, the rising prevalence of neurological diseases and healthcare inequities drive demand for improved MSA diagnostics and therapies, accelerating MSA therapeutics market expansion.

Recent advances in imaging and biomarker identification have increased the accuracy and timeliness of MSA diagnosis. According to the American Association for the Advancement of Science (AAAS), the development of 2D materials and microfabrication technologies has resulted in some new secondary labels that have a high potential for biomarker detection due to their improved biocompatibility, larger surface-to-volume ratio, and so on. Overall, enhanced biomarker detection allows for earlier and more accurate MSA diagnosis, which increases demand for tailored therapies and boosts MSA therapeutics market growth.

Currently, there is no cure for MSA, and existing treatments focus on symptom management rather than disease progression. This constraint impedes patient outcomes and inhibits market progress, as the demand for effective medicines remains unmet.

Research is increasingly focusing on medicines that target the underlying causes of MSA, such as alpha-synuclein aggregation. Success in this field could alter treatment approaches, presenting hope for slowing or reversing disease progression and growing the MSA therapeutics market.

Multiple System Atrophy Therapeutics Market Segmentation

The worldwide market for multiple system atrophy therapeutics is split based on product, mechanism of action, end-user, and geography.

Multiple System Atrophy Therapeutics Market By Product

• Anle-138b
• Azd-3241
• Cs-10br05
• Npt-20011
• Pbt-434
• Pd-01

According to multiple system atrophy therapeutics industry analysis, Anle-138b is a major treatment candidate on the market, targeting pathogenic alpha-synuclein oligomers and potentially altering disease development. The four segments—AZD-3241, CS-10BR05, NPT-20011, PBT-434, and PD-01—are also being investigated for MSA treatment, with each employing a distinct method of action. These therapies are in various phases of development, helping to provide a diversified and growing therapeutic environment for MSA.

Multiple System Atrophy Therapeutics Market By Mechanism of Action

• Suppressing inflammation
• Restoring neuronal function
• Targeting disease pathways
• Protecting against neurotoxicity

According to multiple system atrophy therapeutics industry analysis, most common method of action is to target disease pathways, notably with alpha-synuclein inhibitors. This emphasis arises from the central role of alpha-synuclein protein buildup in MSA pathogenesis, which makes it a prime target for therapeutic intervention. Other methods, such as lowering inflammation and restoring neuronal function, are being investigated in order to address the neuroinflammatory and neuronal deterioration associated with MSA. Furthermore, neurotoxicity prevention strategies aim to prevent further neuronal damage by reducing toxic shocks to the nervous system.

Multiple System Atrophy Therapeutics Market By End-User

• Hospital
• Clinic
• Others

According to multiple system atrophy therapeutics market forecast, hospitals dominate the end-user sector because they have modern healthcare infrastructure and access to specialized neurology departments. They provide extensive diagnostic services, allowing for accurate and timely detection of MSA, which is critical for optimal illness management. In addition, hospitals are equipped to give complex therapy regimens such as intravenous medicines and other modern therapies. Their ability to provide multidisciplinary care, incorporating neurologists, physiotherapists, and support workers, enhances their dominant position in the MSA therapies market.

Multiple System Atrophy Therapeutics Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of LATAM

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Multiple System Atrophy Therapeutics Market Regional Analysis

In terms of regional segments, North America dominates the multiple system atrophy (MSA) therapeutics market because of the increasing prevalence of neurodegenerative illnesses in nations such as the United States, Canada, and others. For example, the National Institute of Environmental Health Sciences projects that up to 6.2 million people in the United States may have Alzheimer's disease by 2022, according to an Alzheimer's Disease Association report. The Parkinson's Foundation estimates that about a million Americans suffer from Parkinson's disease. Additionally, increased research and development activities in the North American region will boost industry growth in the forecast period 2025 to 2033.

Asia-Pacific is the fastest expanding region in the multiple system atrophy (MSA) therapeutics market, owing to the increasing incidence of neurological disorders and the aging population in nations such as China, India, Japan, South Korea, and others. For example, the contribution of noncommunicable neurological disorders to total DALYs in India quadrupled from 4.0% (95% UI 3.2-5.0) in 1990 to 8.2% (6.6-10.2) in 2019, whereas the contribution of injury-related neurological disorders increased from 0.2% (0.2-0.3) to 0.6% (0.5-0.7). This increased knowledge may lead to an increase in demand for therapeutic choices, as patients and healthcare practitioners actively seek management solutions for such chronic illnesses. As a result, pharmaceutical companies may invest more in R&D and introduce innovative medicines to the market, fueling multiple system atrophy (MSA) therapeutics market growth.

Multiple System Atrophy Therapeutics Market Players

Some of the top multiple system atrophy therapeutics companies offered in our report includes Prana Biotechnology Ltd, Sumitomo Dainippon Pharma Co., Ltd, AstraZeneca Plc, MitoDys Therapeutics Ltd, Modag GmbH, Biohaven Pharmaceuticals, Inc, Theravance Biopharma, Inc, Neuropore Therapies Inc, AFFiRiS AG, ProMIS Neurosciences Inc, and Corestem Inc.

TABLE OF CONTENT